Human hydroxysteroid dehydrogenase-like protein 2 (HSDL2) is a member of the short-chain dehydrogenase/reductase (SDR) subfamily of oxidoreductases and contains an N-terminal catalytic domain and a C-termianl sterol carrier protein type 2 (SCP-2) domain. In this study, the C-terminal SCP-2 domain of human HSDL2, including residues Lys318-Arg416, was produced in Escherichia coli, purified and crystallized. X-ray diffraction data were collected to 2.10 Å resolution. The crystal belonged to the trigonal space group P3 1 21 (or P3 2 21), with unit-cell parameters a = b = 70.4, c = 60.6 Å , = = 90, = 120 . Two protein molecules are present in the asymmetric unit, resulting in a Matthews coefficient of 2.16 Å 3 Da À1 and an approximate solvent content of 43%. research communications Acta Cryst. (2015). F71, 901-905 Cheng et al. SCP-2 domain of human hydroxysteroid dehydrogenase-like protein 2 905
Introduction
Short-chain dehydrogenases/reductases (SDRs) are enzymes within the class of NAD(P)(H)-dependent oxidoreductases (Oppermann et al., 2003; Bhatia et al., 2015) . Over 80 genes have been identified that encode enzymes with this function in carbohydrate, amino-acid and steroid hormone metabolism. To date, more than 20 000 SDRs have been found in prokaryotes and eukaryotes (Kowalik et al., 2009 ). Owing to their pivotal roles in the regulation of different metabolic and signalling pathways, the dysfunction of SDR enzymes can lead to several diseases such as Alzheimer's disease, cancer and obesity-related medical conditions (Oppermann et al., 1999; Chang et al., 2005; Moeller & Adamski, 2006; Persson et al., 2009) . Therefore, these human SDRs constitute enzymes that may be interesting targets for drug development (Oppermann et al., 2003; Zhang et al., 2005) .
Human hydroxysteroid dehydrogenase-like 2 (HSDL2; NCBI Reference Sequence NP_115679.2), which contains one polypeptide chain of 418 amino-acid residues, is a member of the short-chain dehydrogenase/reductase (SDR) subfamily of the oxidoreductases (Dai et al., 2003) . This enzyme is a ubiquitously expressed enzyme consisting of an N-terminal SDR domain and a C-terminal sterol carrier protein type 2 (SCP-2)-like domain containing a peroxisomal targeting signal (ARL). A search for regions of local similarity between sequences of human HSDL2 and other SDRs using the Basic Local Alignment Search Tool (BLAST; Altschul et al., 1990; Oehmen & Baxter, 2013) revealed that the N-terminal SDR domain consists of residues Leu8-Ile249 and the C-terminal SCP-2 domain consists of residues Lys318-Met411. Subcellular localization studies and a screening assay for substrates ISSN 2053-230X # 2015 International Union of Crystallography of HSDL2, including steroid hormones and retinoids, revealed that a significant conversion of steroid hormones did not occurr. The peroxisomal localization of human HSDL2 may suggest an involvement in fatty-acid metabolism (Kowalik et al., 2009) . The substrate specificity of this enzyme is unknown.
SCP-2, also known as nonspecific lipid-transfer protein, is a 13.3 kDa protein that is conserved among bacteria, archaea and eukaryotes. SCP-2 is specifically targeted to peroxisomes via a C-terminal peroxisomal targeting signal 1 (PTS1), where it is likely to be involved in peroxisomal -oxidation of fatty acids (Kowalik et al., 2009) . Interestingly, SCP-2-deficient mice show an accumulation of methyl-branched fatty acids, which suggests a physiological role for SCP-2 in -fatty acid oxidation (Lige et al., 2009) . The most C-terminal SCP-2 carries a PTS1 that directs the protein to vesicles before processing. Deletion of this signal results in accumulation of SCP-2 in the cytoplasm (Lige et al., 2009) .
In mammalian cells, the SCP-2 domain harbours a PTS1 and is responsible for the transport of D-bifunctional protein (DBP) to peroxisomes (Gallegos et al., 2001) . In peroxisomes, DBP undergoes proteolytic cleavage at a site between the two enzyme domains. These domains take part in peroxisomal oxidation of fatty acids through d-3-hydroxyacyl-CoA intermediates. It is possible that SCP-2 facilitates these reaction cycles by providing lipid substrates to the enzymatic active sites. The research showed that the C-terminus represents a subcellular localization signal in the parasite. It has been shown that the DBP C-terminal domain carries a subcellular localization signal in the parasite Toxoplasma gondii. Shifting the PTS1 from the C-terminus towards the centre of SCP-2 or deleting this motif results in cytosolic localization of the T. gondii DBP protein (Lige et al., 2009) . These results suggest that the C-terminus is critical for the interaction with the receptor and therefore the proper localization of the protein in the parasite. In mammalian cells, the 58 kDa SCP-x protein is partially post-translationally cleaved to an N-terminal 46 kDa protein (3-oxoacyl-CoA thiolase) and a C-terminal 13 kDa SCP-2 (Martin et al., 2008) . To date, no information exists on the mechanism of cleavage, by autocatalysis or protease mediation, of mammalian SCP-2-containing proteins or on the cleavage-site residues.
A crystal structure of the N-terminal SDR domain binding to nicotinamide adenine dinucleotide phosphate (NADP) has previously been solved (PDB entry 3kvo; Structural Genomics Consortium, unpublished work). However, the crystal structures of full-length human HSDL2 and the C-terminal SCP-2 domain have still not been determined. We have therefore crystallized the C-terminus of SCP-2 to explore the possible molecular mechanism of this protein. The results of crystallization and preliminary crystallographic studies are reported in this paper.
Materials and methods

Macromolecule production and purification
The cDNA encoding the SCP-2 domain (residues Lys318-Leu418) of human HSDL2 was amplified by polymerase chain reaction using full-length human complementary DNA as a template, which was cloned using reverse transcription of the messenger RNA extracted from HeLa cells using TRIzol reagent (Invitrogen). The cDNA was cloned into the expression vector pProEX HTb (Novagen) as a fusion with an N-terminal His tag and a tobacco etch virus (TEV) protease cleavage site. The protein-production information is given in Table 1 . The recombinant C-terminal SCP-2 domain of human HSDL2 was expressed in Escherichia coli strain BL21(DE3) CodonPlus RIL cells (Stratagene, USA).
Purification of the C-terminal SCP-2 domain of human HSDL2 was carried out at 277 K. The E. coli cells were harvested by centrifugation, resuspended in lysis buffer (20 mM Tris-HCl buffer pH 8.0 containing 500 mM NaCl and 20 mM imidazole) and lysed by sonication. Cell debris was removed by centrifugation at 16 000g for 20 min. The supernatant was loaded onto a HisTrap column (5 ml) equilibrated with lysis buffer. After washing the column with lysis buffer, the His-tagged C-terminal SCP-2 domain of human HSDL2 was eluted with 20 mM Tris-HCl buffer pH 8.0 containing 500 mM NaCl and 500 mM imidazole. The sample buffer was exchanged to 20 mM Tris-HCl buffer pH 8.0 containing 500 mM NaCl and 20 mM imidazole using a HiPrep 26/10 desalting column. The His tag was cleaved with 140 ml TEV protease (4 mg ml À1 ) at 277 K overnight. To remove the uncleaved His-tagged protein, the reaction solution (14 ml) was loaded onto a HisTrap column (5 ml) as described above. The flowthrough fractions were collected and desalted on a HiPrep 26/10 desalting column with 20 mM Tris-HCl buffer pH 8.0 containing 5 mM -mercaptoethanol (ME). The pooled fraction (30 ml) was loaded onto a HiTrap Q column (5 ml) equilibrated with 20 mM Tris buffer pH 8.5 containing 5 mM ME and 10 mM NaCl, and the C-terminal SCP-2 domain of human HSDL2 was eluted with a linear gradient of 10 mM to 1 M NaCl. Finally, the purified protein fraction (6 ml) was concentrated to 1.1 ml using an Amicon Ultra-15 filter (5000 MWCO, Millipore) and was loaded onto a HiLoad 16/60 Superdex 75 column equilibrated with 20 mM Tris-HCl Table 1 Macromolecule-production information.
Source organism
Homo sapiens DNA source Full-length complementary DNA from HeLa cell Forward primer †
Cloning vector pProEX HTb Expression vector pProEX HTb Expression host E. coli strain BL21(DE3) CodonPlus RIL Complete amino-acid sequence of the construct produced § MSYYHHHHHHDYDAPTTENLYFQGAKDSLSDDVV KATQAIYLFELSGEDGGTWFLDLKSKGGNVGY-GEPSDQADVVMSMTTDDFVKMFSGKLKPTMAF-MSGKLKIKGNMALAIKLEKLMNQMNARL † The forward primer contains an NarI restriction site (underlined). ‡ The reverse primer contains an EcoRI restriction site (underlined) and a stop codon (italic). § The amino-acid sequence of the SCP-2 domain is shown in italics and the TEV protease cleavage site is underlined. The peptide bond between the Q and G residues is cleaved by TEV protease.
buffer pH 8.0 containing 150 mM NaCl and 2 mM dithiothreitol (DTT). All chromatography materials were purchased from GE Healthcare Biosciences. Approximately 7.5 mg of the SCP-2 domain of human HSDL2 was obtained from 50 g of E. coli cells.
Crystallization
The purified C-terminal SCP-2 domain of human HSDL2 was concentrated to approximately 15 mg ml À1 using an Amicon Ultra-15 (MWCO 3000) filter unit (Millipore). The concentration of the protein solution (500 ml) prior to crystallization was determined using UV spectrophotometry. Crystallization conditions are listed in Table 2 . Crystal Screen HT, PEG/Ion and Index (Hampton Research) were used to establish initial crystallization conditions. Several single crystals with approximate dimensions of 0.2 Â 0.1 Â 0.1 mm were obtained using condition No. 46 [100 mM bis-tris pH 6.5, 20%(w/v) PEG MME 5000] of the Index screen within 3 d (Fig. 1) .
Mass assay of crystallized protein
The crystals from 20 drops were harvested by centrifugation at 12 000g for 10 min at 277 K and the supernatant was removed with a micropipette. To remove the noncrystallized protein completely, the crystals were resuspended in 1 ml of solution No. 46 of the Index screen (Hampton Research) and the crystals were harvested using the same centrifugation protocol as described above. The supernatant was removed. These operations were repeated five times and the final harvested crystals were dissolved in 20 ml water.
2 ml protein solution was spotted onto a target of the Clin-TOF instrument. After the protein solution had dried at room temperature, 1 ml of a solution containing 5 mg ml À1 -cyano-4-hydroxycinnamic acid, 50%(v/v) acetonitrile and 1%(v/v) trifluoroacetic acid was added to the protein spot. After this solution had dried at room temperature, MALDI-TOF MS measurements were performed using a Clin-TOF instrument (Bioyong Technologies Inc.). The profile spectra were acquired from an average of 400 laser shots per sample with peak intensities (measured as m/z) in the mass range 1000-20 000 Da. The molecular weight of the SCP-2 domain of human HSDL2 was determined by MALDI-TOF/TOF MS operated in linear mode.
Data collection and processing
A single crystal with approximate dimensions of 0.2 Â 0.1 Â 0.1 mm was swished about to remove the reservoir solution using a cryoprotectant solution consisting of 66.6%(v/v) Paratone-N, 28.6%(v/v) paraffin and 4.8%(v/v) glycerol. The crystal was mounted on a rayon loop in a liquid-nitrogen gas stream at 100 K. X-ray diffraction data from the crystal were collected on beamline BL17U at Shanghai Synchrotron Radiation Facility (SSRF; Shanghai, People's Republic of China). The X-ray diffraction data-collection information is summarized in Table 3 . Diffraction intensity data were processed and scaled using HKL-2000 (Otwinowski & Minor, 1997) . The crystal parameters are shown in Table 3 . Table 2 Crystallization conditions for the SCP-2 domain of human HSDL2.
Method
Sitting-drop vapour diffusion Plate type CrystalEX (Corning) 96-well crystallization plate (Hampton Research) Temperature (K) 293 Protein concentration (mg ml À1 ) 1 5 Buffer composition of protein solution 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM DTT Composition of reservoir solution 100 mM bis-tris pH 6.5, 20%(w/v) PEG MME 5000 Volume and ratio of drop 2 ml (1 ml protein solution + 1 ml reservoir solution) Volume of reservoir (ml) 200
Figure 1
Typical single crystals of the C-terminal SCP-2 domain of human HSDL2. N(hkl) is the data redundancy, I i (hkl) is the observed intensity and hI(hkl)i is the mean intensity from multiple observations of symmetry-related reflections.
Results and discussion
X-ray diffraction data were collected to 2.10 Å resolution. The crystal of the C-terminal SCP-2 domain of human HSDL2 belonged to the trigonal crystal system, with unit-cell parameters a = b = 70.4, c = 60.6 Å , = = 90, = 120 . Processing the X-ray diffraction data in space groups P321 or P312 resulted in an overall R merge of 6.7 or 45.9%, respectively. The 0, k, l X-ray diffraction images displayed using the phenix. data_viewer program in the PHENIX suite (Adams et al., 2010) revealed that the allowed reflections are 0, 0, l = 3n. Therefore, the space group of the crystal of the C-terminal SCP-2 domain of human HSDL2 is P3 1 21 (or P3 2 21). Clin-TOF mass spectrometry identified that the crystallized protein has a molecular weight of 10 934.33 Da (Fig. 2) . This result revealed that the crystallized SCP-2 domain of human HSDL2 contains residues Lys318-Arg416 (with a theoretical molecular weight of 10 933.67 Da). Therefore, calculation of the Matthews coefficient and solvent content of this protein crystal (Matthews, 1968; Kantardjieff & Rupp, 2003) using the MATTHEWS_COEF program from the CCP4 suite (Winn et al., 2011) suggested that two protein molecules are present in the asymmetric unit, resulting in a Matthews coefficient of 2.16 Å 3 Da À1 and an approximate solvent content of 43%.
The self-rotation function calculated using MOLREP (Vagin & Teplyakov, 2010) revealed no additional twofold symmetry peaks besides those owing to crystallographic symmetry (Fig. 3) . The phenix.xtriage program in the PHENIX suite (Adams et al., 2010) showed that the largest off-origin peak in the native Patterson function is 6.39% of the height of the origin peak. These results suggest that no noncrystallographic symmetry can be detected.
Molecular-replacement (MR) searches were performed using the MrBUMP program (Keegan & Winn, 2007) to solve the crystal structure of the SCP-2 domain of human HSDL2. The programs MOLREP (Vagin & Teplyakov, 2010) and Phaser (McCoy et al., 2007) and the crystal structures of the TPR domain of human Pex5p in complex with human Mscp2 (PDB entry 2c0l; 40% sequence identity; Stanley et al., 2006) were used to search for a solution; however, a correct solution has not been found. In addition, two crystal structures of SCP-2 domains with 38% sequence identity to the SCP-2 domain of human HSDL2 were also used as MR search models: the SCP-2 domain from the yeast Yarrowia lipolytica (PDB entry 4jgx; De Berti et al., 2013) and the SCP-2 domain from rabbit (PDB entry 1c44; Choinowski et al., 2000) . The crystal packing of each MR solution obtained using each of the mentioned structures as a search model revealed that two molecules clash. As no correct MR solutions were found with these models, the isomorphous replacement (IR) method or multiwavelength anomalous dispersion (MAD) method is presently being utilized to solve the crystal structure of the SCP-2 domain of human HSDL2.
Figure 2
Clin-TOF mass spectrum of the crystallized SCP-2 domain of human HSDL2.
Figure 3
Plot of the self-rotation function calculated using X-ray diffraction data in the resolution range 20.0-3.0 Å in the = 180 section. The map is contoured from the 1.0 level in steps of 1.0.
